Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investor Events
  • Pre-market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
April 1, 2022 2:37 PM 1 min read

Read How Analysts Reacted To Blend Labs' Q4 Results

by Anusuya Lahiri Benzinga Editor
Follow
BLND Logo
BLNDBlend Labs Inc
$1.67-0.32%
Overview
Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.


Posted In:
Analyst ColorNewsPenny StocksDowngradesPrice TargetReiterationSmall CapAnalyst RatingsMoversTechTrading IdeasBriefs
  • Analysts mainly slashed the price targets or downgraded the rating on Blend Labs Inc (NYSE:BLND) post Q4 results.
  • KeyBanc analyst Josh Beck lowered the price target to $6 from $10 (26% upside) and kept an Overweight. 
  • The company's FY22 revenue forecast was well below the Street's $343.8 million, reflecting the negative impact of higher rates on the mortgage market.
  • Canaccord analyst Joseph Vafi downgraded Blend Labs to Hold from Buy with a price target of $5, down from $28 (5% upside).
  • Vafi noted that share gains in 2022 likely cannot entirely offset estimated overall mortgage volume declines given the macro environment.
  • Truist analyst Terry Tillman lowered the price target to $5.50 from $7.50 (16% upside) and kept a Hold. 
  • Tillman specified that the company's Q1 and FY22 outlook was well below Street view.
  • The analyst remains cautious about the potential for further negative estimate revisions and the lack of clarity around cost savings initiatives.
  • Piper Sandler analyst Arvind Ramnani downgraded Blend Labs from Overweight to Neutral and lowered the price target from $10 to $5.5 (16% upside).
  • Wells Fargo analyst Michael Turrin downgraded Blend Labs from Overweight to Equal-Weight with a $5 price target (5% upside).
  • Price Action: BLND shares traded lower by 16.58% at $4.76 on the last check Friday.
BLND Logo
BLNDBlend Labs Inc
$1.67-0.32%
Overview
Comments
Loading...